Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | MLNR | O43193 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bephenium SCHEMBL9118297 | 0.98 | HTT (0.58) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| Bephenium SCHEMBL9181734 | 0.98 | SMN1; SMN2 (0.59) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL9180609 | 0.91 | DNM1 (0.59) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL9324544 | 0.90 | SMN1; SMN2 (0.70) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9179821 | 0.89 | MEN1 (0.60) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL5156049 | 0.89 | SMN1; SMN2 (0.70) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL9187376 | 0.84 | CHRM2 (0.50) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL9539266 | 0.84 | ALOX5 (0.54) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL24465407 | 0.82 | CHRNA7 (0.65) | CHRM2ADRA2ACHRM1ADRA2BADRA2C | |
| SCHEMBL19912115 | 0.81 | CHRM2 (0.62) | CHRM2ADRA2ACHRM1ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4586826-A1 | FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL | In the Bowl Animal Health, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | claimed |
| WO-2024264012-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS INCLUDING ANTHELMINITIC BENZIMIDAZOLE COMPOUNDS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | IC-MedTech Corp. | 2024-05-23 | — | — | US | claimed |
| WO-2024059837-A1 | FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL | IN THE BOWL ANIMAL HEALTH, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2024-01-16 | — | — | US | claimed |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | MARINGA STATE UNIVERSITY (BR) | 2021-11-25 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8147561-B2 | Methods and devices to curb appetite and/or reduce food intake | ENDOSPHERE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060178691-A1 | Methods and devices to curb appetite and/or reduce food intake | THE DIRECTOR OF DEVELOPMENT OF THE STATE OF OHIO | 2006-08-10 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0606756-B1 | Use of disulfonyl methanes for the control of parasites | LILLY CO ELI (US) | 1997-07-23 | — | — | EP | claimed |
| US-5614525-A | ANTHELMINTICS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0507629-B1 | Sustained release capsule and formulations for insertion into rumen | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0549773-B1 | ETHER-CONTAINING QUATERNARY AMMONIUM SALTS | EASTMAN KODAK CO (US) | 1995-07-05 | — | — | EP | claimed |
| CN-1094225-A | Prevent and treat the bephenium missible oil of resistance aphid | SUN CHENGJUN (CN) | 1994-11-02 | — | — | CN | claimed |
| EP-0606756-A1 | Use of disulfonyl methanes for the control of parasites | ELI LILLY AND COMPANY (US) | 1994-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | CHRM2 1443/4885ADRA2A 1259/4885CHRM1 1311/4885 |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | CHRM2 1443/4885ADRA2A 1259/4885CHRM1 1311/4885 |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | CHRM2 1443/4885ADRA2A 1259/4885CHRM1 1311/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | CHRM2 1443/4885ADRA2A 1259/4885CHRM1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.